Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0100191136
Fri, 30.08.2024
Relief Therapeutics Holding SA
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks
RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025
Streamlined operations and CHF 15.1 million cash reserves expected to p [ … ]
Mon, 05.08.2024
Relief Therapeutics Holding SA
Relief Therapeutics Secures up to $11 Million from Royalty SalesNon-dilutive funding to support RLF-TD011 clinical development and pipeline advancement
GENEVA (Aug. 5, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for [ … ]
Thu, 27.06.2024
Relief Therapeutics Holding SA
.awlist1_1719466159_233481 { list-style:none; counter-set:awlistcounter1 }
.awlist1_1719466159_233481 li:before { content:'5.' counter(awlistcounter1); counter-increment:awlistcounter1 }
.awlist2_1719466159_233481 { list-style:none; counter-set:awlistcounter2 1 }
.awlist2_1719466159_233481 li:before { content:'5.' counter(awlistcounter2); [ … ]
Mon, 03.06.2024
Relief Therapeutics Holding SA
Relief Therapeutics Announces Executive Changes
GENEVA (June 3, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that interim Chief Executive [ … ]
Mon, 03.06.2024
Relief Therapeutics Holding SA
Relief Therapeutics Announces Executive Changes
GENEVA (June 3, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that interim Chief Executive [ … ]
Thu, 30.05.2024
Relief Therapeutics Holding SA
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
GENEVA (MAY 30, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Meeting (AGM) o [ … ]
Wed, 08.05.2024
Relief Therapeutics Holding SA
Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives
GENEVA (MAY 8, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for sel [ … ]
Wed, 08.05.2024
Relief Therapeutics Holding SA
Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives
GENEVA (MAY 8, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for sel [ … ]
Tue, 30.04.2024
Relief Therapeutics Holding SA
Relief Therapeutics has published its Annual Report
GENEVA (APR. 30, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its Annual Report 2023 and provided a corporate update. [ … ]
Wed, 27.03.2024
Relief Therapeutics Holding SA
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General MeetingRelief Therapeutics Calls Extraordinary General Meeting
Anticipated Board of Directors Overhaul
GENEVA (MAR. 27, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innova [ … ]